Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2007-11-20
2007-11-20
Harris, Alana M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S350000, C530S326000, C530S328000, C436S064000, C436S086000
Reexamination Certificate
active
10736227
ABSTRACT:
The present invention relates to a novel polypeptide (BCMP 101) compositions comprising the polypeptide, including vaccines, and antibodies that are immunospecific for the polypeptide. The use of the polypeptide in the diagnosis, prophylaxis and treatment of cancer, in particular breast cancer is also provided.
REFERENCES:
patent: 5776687 (1998-07-01), Nagpal et al.
patent: 2003/0092898 (2003-05-01), Salceda et al.
patent: WO 00/55628 (2000-09-01), None
patent: WO 01/13117 (2001-02-01), None
patent: WO 01/13117 (2001-02-01), None
patent: WO 02/64611 (2002-08-01), None
Amino acid databases, GenCore. Sequence alignment between US 2003/0092898 A1 sequence 267 and Applicants' SEQ ID No: 1, May 15, 2003.
Amino acid databases, GenCore. Sequence alignment between US Patent 5,776,687 sequence 12 and Applicants' SEQ ID No: 1, Jul. 7, 1998.
Baselga, J., et al., Recombinant Humanized Anti-HER2 Antibody(Herceptin™)Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2
eu Overexpressing Human Breast Cancer Xenografts1, 1998, Cancer Res. 58: 2825-2831.
Catimel, B., et al., Purification and Characterization of a Novel Restricted Antigen Expressed by Normal and Transformed Human Colonic Epithelium, 1996, J. Biol. Chem. 271:25664-25670.
ABSTRACT for Craggs, et al., 2003, Applied Genomics & Proteomics 2(2):101-100.
Davis, ID,et al.,An overview of Cancer immunotherapy,2000, Immunol Cell Biol. 78: 179-196.
Dillman, R.O.,Perceptions of Herceptin®:A Monoclonal Antibody for the Treatment of Breast Cancer, 1999, Cancer Biother. Radiopham. 14: 5-10.
Green,MC,etal,Monoclonal antibody therapy for solid tumors,2000,Cancer Treat Rev 26:269-86.
Hubert, R.S. et al., STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors, 1999, Pro. Natl Acad. Sci. USA 96: 14523-14528.
Knuth, A. et al., Cancer immunotherapy in clinical oncology,2000, Cancer Chemother. Pharmacol. 46, S46-51.
Lucas S., et al., MAGE-5B, MAGE-B6, MAGE-C2, and MAGE-C3: Four New Members Of The MAGE Family With Tumor-Specific Expression, 2000, Int.J. Cancer 87:55-60.
Miller, K.D., et al., Toward checkmate:biology and breast cancer therapy for the new millennium, 1999, Invest.New Drugs 17: 417-427.
Saffran, D.C., et al., Targget antigens for prostate cancer immunotherapy, 1999, Cancer Metastasis Rev. 18: 437-449.
Shiku, H., et al.,Development of a cancer vaccine: peptides, proteins, and DNA 2000, Cancer Chemother. Pharmacol. 46:S77-82.
Stebbing, J., et al.,Herceptin (transtuzamab) in advanced breast cancer, 2000, Cancer Treat. Rev. 26:287-290.
Vermeulen, S.J., et al., The αE-catenin gene (CTNNA1) acts as an invasion-suppressor gene in human colon cancer cells, 1999, Oncogene 18: 905-915.
Database EMBL online Dec. 1, 2001 “NSE2 Protein” Database Accession No. Q96Kn1 XP002234948.
Harris Alana M.
Klauber & Jackson
UCB Pharma S.A.
LandOfFree
Cancer associated protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer associated protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer associated protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3837950